Compare UMBF & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | UMBF | ABVX |
|---|---|---|
| Founded | 1913 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5B | 9.2B |
| IPO Year | N/A | N/A |
| Metric | UMBF | ABVX |
|---|---|---|
| Price | $128.43 | $125.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 11 |
| Target Price | ★ $141.40 | $130.09 |
| AVG Volume (30 Days) | 602.2K | ★ 836.0K |
| Earning Date | 01-27-2026 | 03-23-2026 |
| Dividend Yield | ★ 1.34% | N/A |
| EPS Growth | ★ 3.34 | N/A |
| EPS | ★ 9.29 | N/A |
| Revenue | ★ $2,497,755,000.00 | $6,231,374.00 |
| Revenue This Year | $17.75 | $6.80 |
| Revenue Next Year | $6.36 | N/A |
| P/E Ratio | $13.86 | ★ N/A |
| Revenue Growth | ★ 59.30 | N/A |
| 52 Week Low | $82.00 | $4.77 |
| 52 Week High | $136.11 | $148.83 |
| Indicator | UMBF | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 54.37 | 57.81 |
| Support Level | $121.23 | $115.93 |
| Resistance Level | $136.11 | $125.48 |
| Average True Range (ATR) | 3.77 | 4.82 |
| MACD | -0.22 | 1.33 |
| Stochastic Oscillator | 47.11 | 96.87 |
UMB Financial Corp, or UMBF, is a financial services holding company offering a suite of banking services and asset servicing to its customers in the United States and around the world. Its client base includes commercial, institutional, and personal customers. Along with its subsidiaries, the company operates in the following business segments: Commercial Banking, Institutional Banking, and Personal Banking. A majority of its revenue is generated from the Commercial Banking segment, which serves the commercial banking and treasury management needs of small to middle-market businesses through various products and services such as commercial loans, commercial real estate financing, commercial credit cards, letters of credit, loan syndication services, consultative services, and others.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.